NIRLON vs SICAGEN: Stock Comparison
NIRLON is the larger company by market capitalisation. NIRLON shows a higher ROE, a higher dividend yield and a higher ROCE, while SICAGEN INDIA shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NIRLON leads 6; SICAGEN leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | NIRLON | SICAGEN |
|---|---|---|
| Live Price | ₹625.25 | ₹51.48 |
| Day Change | -0.17% | 1.12% |
| Volume | 2,583 | 382 |
| 52-Week High | ₹657 | ₹74.06 |
| 52-Week Low | ₹516.03 | ₹46.55 |
| Distance from 52W High | -4.83% | -30.49% |
Valuation
| Metric | NIRLON | SICAGEN |
|---|---|---|
| Market Cap | ₹5,634 Cr | ₹198 Cr |
| P/E Ratio | 15.78x | 11.41x |
| P/B Ratio | 12.02x | 0.47x |
| EPS | ₹7.7 | ₹1.75 |
| Book Value | ₹52 | ₹125.09 |
| Dividend Yield | 4.78% | 1.98% |
Growth
| Metric | NIRLON | SICAGEN |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -1.54% | 2.9% |
| Qtr Profit Growth | -1.71% | 55.38% |
Profitability & Leverage
| Metric | NIRLON | SICAGEN |
|---|---|---|
| ROE | 73.83% | 3.07% |
| ROCE | 27.8% | 4.15% |
| Net Margin | 51.7% | 1.86% |
| Operating Margin | 71.7% | 4.48% |
| Debt to Equity | 2.45x | 0.13x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NIRLON | SICAGEN |
|---|---|---|
| Promoter Holding | 2.71%▼ 0.01 pp | 23.92% |
| FII Holding | 4.49%▼ 11.29 pp | 2.47% |
| DII Holding | 0.02%▼ 0.06 pp | 0.58% |
| Public Holding | 27.84%▲ 11.37 pp | 35.81% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NIRLON and SICAGEN INDIA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.